U.S. Markets close in 3 hrs 8 mins

Breakfast Technical Briefing on Mirati Therapeutics and Three Other Additional Biotech Stocks

Stock Research Monitor: KTOV, LOXO, and MDGL

LONDON, UK / ACCESSWIRE / July 17, 2018/ If you want a free Stock Review on MRTX sign up now at www.wallstequities.com/registration. Today, WallStEquities.com presents for assessment Kitov Pharma Ltd (NASDAQ: KTOV), Loxo Oncology Inc. (NASDAQ: LOXO), Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL), and Mirati Therapeutics Inc. (NASDAQ: MRTX). These stocks are part of the Biotechnology sector, which harnesses biological processes to create technologies and products for a wide variety of challenges - from expanding crop sizes to treating disease. All you have to do is sign up today for this free limited time offer by clicking the link below.


Kitov Pharma

Tel Aviv, Israel headquartered Kitov Pharma Ltd’s shares dropped 5.53%, closing Monday’s trading session at $2.22. The stock recorded a trading volume of 241,539 shares. Shares of the Company have surged 62.04% over the past year. The stock is trading 7.90% below its 200-day moving average. Additionally, shares of Kitov Pharma, which through its subsidiaries, operates as a development stage biopharmaceutical company in Israel, have a Relative Strength Index (RSI) of 30.78. Get the full research report on KTOV for free by clicking below at:


Loxo Oncology

On Monday, shares in Stamford, Connecticut headquartered Loxo Oncology Inc. recorded a trading volume of 438,573 shares. The stock declined 2.25%, ending the day at $175.00. The Company’s shares have advanced 31.14% in the previous three months and 135.18% over the past year. The stock is trading above its 50-day and 200-day moving averages by 4.43% and 50.43%, respectively. Furthermore, shares of Loxo Oncology, which develops and sells medicines for patients with genetically defined cancers in the US, have an RSI of 50.72. LOXO’s complimentary research coverage is a few simple steps away at:


Madrigal Pharmaceuticals

West Conshohocken, Pennsylvania headquartered Madrigal Pharmaceuticals Inc.’s stock finished the day 2.94% lower at $288.02 with a total trading volume of 118,219 shares. Shares of the Company have skyrocketed 149.48% in the previous three months and 1,767.83% over the past year. The stock is trading above its 50-day and 200-day moving averages by 27.56% and 129.01%, respectively. Additionally, shares of Madrigal Pharma, which focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases, have an RSI of 58.11.

On June 28th, 2018, research firm Raymond James initiated a 'Market Perform' rating on the Company's stock. Register for your free research report on MDGL at:


Mirati Therapeutics

Shares in San Diego, California headquartered Mirati Therapeutics Inc. ended yesterday’s session 0.61% lower at $48.95. The stock recorded a trading volume of 281,412 shares. The Company’s shares have surged 58.16% over the previous three months and 1,155.13% over the past year. The stock is trading 12.11% and 75.69% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Mirati Therapeutics, which develops targeted therapeutics to address the genetic, epigenetic, and immunological promoters of cancer, have an RSI of 54.00.

On June 25th, 2018, Mirati Therapeutics announced that it has been added to the Russell 2000® Index, effective as of the open of the market that day, following Russell’s annual reconstitution of its comprehensive set of US and global equity indexes. The Russell 2000® Index measures the performance of the small-cap segment of the US equity market.

On July 09th, 2018, research firm Oppenheimer reiterated its ‘Outperform’ rating on the Company’s stock with an increase of the target price from $35 a share to $62 a share. Wall St. Equities’ downloadable research report on MRTX available at:


Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit



For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities